Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Core Viewpoint - Ocugen, Inc. has appointed Rita Johnson-Greene as Chief Financial Officer, marking a significant leadership change as the company prepares for transformative developments, including the submission of its first Biologics License Application this year [1][2]. Company Overview - Ocugen, Inc. is a biotechnology leader focused on gene therapies for blindness diseases, utilizing a novel modifier gene therapy platform that addresses complex diseases caused by imbalances in multiple gene networks [4]. - The company is developing programs for inherited retinal diseases and blindness diseases affecting millions globally, including retinitis pigmentosa, Stargardt disease, and geographic atrophy [4]. Leadership Background - Rita Johnson-Greene brings over 20 years of healthcare experience, having previously served as Chief Operating Officer at the Alliance for Regenerative Medicine, where she led operations and finance initiatives [2]. - Her prior roles include Vice President of Sales at Genetix Biotherapeutics, where she supported the launch of gene therapy brands, and senior leadership positions at Spark Therapeutics [2]. - Johnson-Greene holds an MBA in Finance and Strategic Management from The Wharton School and an undergraduate degree in Electrical Computer Engineering from Drexel University [3].